Imprimis Pharmaceuticals Stock Forecast

Sell candidate since Jul 24, 2026 Gain 5.85%

The Imprimis Pharmaceuticals stock price gained 0.643% on the last trading day (Monday, 10th Aug 2026), rising from $40.44 to $40.70. It has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 3.27% from a day low at $39.66 to a day high of $40.95. The price has risen in 7 of the last 10 days and is up by 8.65% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 357 thousand more shares were traded than the day before. In total, 671 thousand shares were bought and sold for approximately $27.30 million.

The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $39.26 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 29.10% during the next 3 months and, with a 90% probability hold a price between $50.69 and $63.95 at the end of this 3-month period.

HROW Signals & Forecast

A buy signal was issued from a pivot bottom point on Monday, July 27, 2026, and so far it has risen 8.65%. Further rise is indicated until a new top pivot has been found. Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Imprimis Pharmaceuticals stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $41.83. On a fall, the stock will find some support from the short-term average at $39.74. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for Imprimis Pharmaceuticals stock

On the downside, the stock finds support just below today's level from accumulated volume at $35.90 and $32.96. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Imprimis Pharmaceuticals finds support just below today's level at $35.90. If this is broken, then the next support from accumulated volume will be at $32.96 and $30.86.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $1.30 between high and low, or 3.27%. For the last week, the stock has had daily average volatility of 3.16%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (HROW) For The Upcoming Trading Day Of Tuesday 11th

For the upcoming trading day on Tuesday, 11th we expect Imprimis Pharmaceuticals to open at $40.44, and during the day (based on 14 day Average True Range), to move between $39.77 and $41.63, which gives a possible trading interval of +/-$1.86 (+/-4.68%) up or down from last closing price. If Imprimis Pharmaceuticals takes out the full calculated possible swing range there will be an estimated 4.68% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $41.94 (3.05%) than the support at $35.90 (11.79%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Imprimis Pharmaceuticals stock A Buy?

Imprimis Pharmaceuticals holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -1.290 Sell Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on August 11, 2026 - $40.44 ( 0.651%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk